ERBB2 and breast cancer: Clinically, 17-AAG shows evidence of successful therapeutic activity in multiple malignancies, mainly in phase I and II clinical trials conducted on cases of HER2+ driven breast cancer, HER2 being a client protein of HSP90 (14).